Pleading wizard

Expert Report of Noriyuki Kasahara, M.D. Ph.D. Expert Witness Statement – Noriyuki Kasahara I, Noriyuki Kasahara, declare the following: As detailed in my Curriculum Vitae, attached herewith as Exhibit B, I am currently an Assistant Professor of Pathology as well as Biochemistry & Molecular Biology, at the Institute for Genetic Medicine of USC/Norris Comprehensive Cancer Center. My educational background includes an M.D.from Tokyo Medical and Dental University as well as a Ph.D from University of California San Francisco. I have numerous scientific publication to my credit, including research studies on gene therapy using retrovirus vectors. I am knowledgeable in the fields of biochemistry and molecular biology and thus I am familiar with the state of the art regarding the sequencing and I. POLYMORPHISMS OR VARIATIONS AMONG THE HUMAN GENOMES
With the exception of identical twins, no human genome is absolutely identical to the genome of another. Genetic differences can be both large and small in scale. Large differences are due to loss or gain of entire genes, gene parts as well as sequences that regulate the gene expression. More common are small, subtle changes of the DNA sequence that can alter the structure and function of the proteins encoded by genes. Such variations are called Single Nucleotide Polymorphisms (SNPs or “snips”). A SNP is estimated to occur once every 1000 base pairs (the total number in a human genome could be as high as 6 million). 1.4 million have already been identified. (International Human Genome Sequencing Consortium (2001) Nature 409: 860-921). Even if only those SNPs that are thought to lie within expressed genes are considered, their number is quite substantial. There is thought to be more than 30,000 genes in the human genome. Currently known SNPs have an average spacing of 1.9 kb, and 63% of 5-kb intervals contain a SNP. Therefore, each person carries 24,000 to 40,000 amino acid-altering sequence substitutions (Cargill M et al. (2000) Nature Genetics, 22: 231-238). II. ISOLATING A GENE RESPONSIBLE FOR THE TRAIT OF HIV RESISTANCE
It is very difficult to determine which of the millions of polymorphisms is responsible for a particular trait. When we get down to the subtle changes, the problem becomes one of a needle in a Expert Witness Statement – Noriyuki Kasahara haystack. It is difficult to determine which sequence differences are truly worth pursuing. One cannot tell which ones lie within the sequences of biological interest, as opposed to the huge stretches of intervening "junk DNA" that comprises the majority of the genome. The genes that encode proteins comprise only a tiny fraction of human DNA, even though they represent the major biological function of the genome. Even if one limits the search to the SNPs within the genes, the Selecting candidate genes
At the current state of technology it is still an immense task to identify genes that might confer a given trait such as resistance to HIV. Often multiple genes are involved in the given biological process as complex as the successful viral infection. In turn, each one of these genes may have deviations from the published sequence. If one is starting from scratch, without any knowledge of what kind of gene it might be and what chromosome it resides on, the task is truly enormous. Such a general screening will yield literally thousands of candidate genes that must be examined. Alternatively, one may pursue a candidate gene approach. An educated guess is made regarding the characteristics of a gene involved in HIV resistance (for example only cell-surface proteins will be examined as they may bind HIV). Such guesses narrow the search parameters. However one runs the risk of missing the Finding polymorphisms within the genes
After the candidate genes are identified one must determine which ones have unusual sequence in a resistant individual. These variations in the sequence may be the ones responsible for the unusual trait. At this time a large scale sequencing effort must be undertaken. Alternatively one may utilize a costly micro-array technology that will simply identify the existence of polymorphisms without pinpointing where they are. This technique will rule out the non- polymorphic genes. An expertly selected micro-array may eliminate a lot of candidates. The detailed sequencing that follows will be done on a more limited scale. Expert Witness Statement – Noriyuki Kasahara Identifying polymorphisms of significance
Next one must establish a nexus between the unusual sequence and unusual trait. This will pinpoint which one of the multitude of variant sequences is responsible for the trait in question. It has been estimated that a gene of average size would contain about 15 SNPs. (Cargill, M. et al. (2000) Nature Genetics, 22, p. 231). As mentioned above, most polymorphisms are irrelevant for the gene function. In addition, phenotypic traits may not be the result of a single alteration in DNA. Instead they may require the combined effects of multiple sequence changes in the same protein, or cumulative changes in a number of proteins that work together. Computer models attempting to predict whether a given amino acid difference is deleterious or favorable are of limited accuracy (Ng, P.C. and Henikoff, S. (2001) Genome Research, 11, p. 863, Sunyaev, S. et al. (2001) Human Molecular Genetics, 10, p. 591)). Therefore one is facing the laborious actual experimentation. Each candidate gene must be tested for its pattern of expression. Such analysis determines where in the body the gene works and when it is active. The genes that are active in the immune system become the more likely candidates for encoding the HIV resistance. Any genes that change their activity in response to HIV infection become good candidates as well. Such analysis involves isolation of messenger RNA from numerous tissues of infected and uninfected individuals. The RNA is probed with the sequence from each one of the candidate genes in order to detect and quantify the gene expression. The latest micro-array technology often simplifies the task of isolating and testing multiple tissues at the same time. However, the reliability of micro-arrays is often questionable: one is running a risk of missing an interesting gene. Confirming the function of the gene and its utility
The in vitro testing phase requires a laborious process of transferring of each candidate gene into an HIV-susceptible cell line. Immortalized cell lines can be used for initial screening, but eventually primary cells (freshly isolated from the body) must be used. Working with primary cells is notoriously difficult. One must use special techniques (preferably a retroviral vector) to achieve the gene transfer and verify that the transferred gene is active. The cell line will then be challenged with HIV. If the cells do not become infected, the transferred DNA may carry an HIV resistance Expert Witness Statement – Noriyuki Kasahara gene. An important control must be done for each candidate gene. The control will employ, for example, the corresponding "non-unique" sequences that occur in the general population. Such SUGGESTED USE OF THE DOLLY GENOME.
The discovery of an HIV resistance gene sequences holds a tremendous potential as a tool for both research into HIV biology and combating AIDS. The use includes but is not limited to the First, the availability of the gene sequence will allow the researchers to isolate the protein and determine precisely how it works. A dominant HIV resistance can be conferred by alterations in any of the steps in the viral life cycle: virus attachment and entry; reverse transcription of viral RNA; transport of the viral material into the nucleus; chromosomal integration of the viral material; viral mRNA transcription, splicing and export from the nucleus; viral protein production and processing; and, finally, virus assembly and budding. The “HIV-resistance gene” will encode a protein that might work in two ways. It may directly interfere with the virus, or it might activate another cellular gene that will do that. For example, the “resistance gene” may code for a variant cytokine (a molecule that the immune system cells use to communicate with each other). A cytokine will bind to and downregulate the HIV co-receptor CCR5 on the surface of the cell. HIV will no longer be able to bind and penetrate such a cell. Understanding how a resistance gene works will shed light on the biology of HIV and the human immune system. Second, the DNA sequences themselves can be used for genetic testing to assess an individual’s susceptibility to HIV infection. The data gathered in the course of such tests will give the public health workers an idea whether particular populations are at a greater risk of an epidemic. In addition, the testing may reveal other similar variations correlating with various levels of Third, the resistance gene can be used to purify a protein with a therapeutic value. The protein may be then administered to AIDS patients by injection or mucosal application. Expert Witness Statement – Noriyuki Kasahara Fourth, the discovered gene may have other effects on the immune system. For example it may affect the system’s responsiveness to immunomodulatory drugs. Thus screening for the presence of this sequence in individuals would have an additional predictive value in Fifth, the Dolly-derived or other cell lines engineered to express the same variant gene can be used for testing to monitor against the emergence of mutant HIV strains. The new strains will manifest themselves by infecting a previously resistant cell line (e.g., by utilizing a different co- Sixth, the engineered cell lines such as CL100 constitutively expressing the variant Dolly gene can be used as "cell factories" for production of the desired protein, which can be harvested, purified, and used as a therapeutic agent. Finally, the identified gene sequences can be used for gene therapy. The gene that encodes the variant protein can be introduced into the immune system cells (T-cells and macrophages) by the use of gene delivery vectors. The altered cells can be used for an autologous transplantation (reintroduction into the same body) into an AIDS patient. These cells will be resistant to infection by HIV present in the patient’s body and repopulate the depleted immune cell supply. ________________________ Noriyuki Kasahara Expert Witness Statement – Noriyuki Kasahara EXHIBIT B
CURRICULUM VITAE OF DR. NORIYUKI KASAHARA, M.D., PH.D. Departments of Pathology and Biochemistry & Molecular Biology and Institute for GeneticMedicine, University of Southern California (i) 2250 Alcazar Street, CSC-240, Los
Angeles, CA, 90033
Tokyo Medical and Dental University undergraduate campus, Tokyo, Japan, 1980-1982. Tokyo Medical and Dental University School of Medicine, Tokyo, Japan, 1982-1986. Baccalaureate Medicinae and medical licensure, 1986. Dept. of Endocrinology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan, 1986. Doctorate in Medical Science, 1993 (for ongoing research). –"Changes in thymidine kinase isoenzyme and thymidylate synthase activities during carcinogenesis." –"Deletional analysis of the human renin promoter." University of California at San Francisco (UCSF), Interdepartmental Graduate Program in Endocrinology, 1986-1994. –"Cell-specific targeting of retroviral vectors via ligand- (research done in the laboratory of Dr. Y.W. Kan, Howard Hughes Medical Institute (HHMI), UCSF) Residency Program in Laboratory Medicine/Clinical Pathology, University of California at San Francisco (UCSF), 1991-1993. Postdoctoral fellowship, laboratory of Dr. Y.W. Kan, 1994-1995. – University of California Regent’s Fellowship Award, 1986 – University of California Non-Resident Tuition Scholarship Award, 1987 Expert Witness Statement – Noriyuki Kasahara – Certificate of Distinction in Teaching for Excellent Small-Group Instruction, UCSF School of Medicine, 1988 & 1990 – Howard Hughes Medical Institute Award in Recognition of Graduate Student Assistance in HHMI Laboratories, 1988, 1989, 1990, & 1991 – Tokyo Medical and Dental University Alumni Association Young – University of California San Francisco Chancellor Julius R. Krevans – Stop Cancer Foundation Career Development Award, 1996 – Institut de Recherches Cliniques de Montreal (Clinical Research Institute of Montreal), Pfizer Travelling Fellowship, 1997 – USC Research Center for Liver Diseases New Investigator Award, 1998 – Cooley's Anemia Foundation Research Fellowship Award, 1998 & 1999 – Medical licensure, Ministry of Health and Welfare of Japan, 1986, – Medical licensure, State of California, 1994, – United States Educational Commission for Foreign Medical Graduates Certification, 1986 Permanent Validation, 1992 – American Board of Pathology (Clinical Pathology), diplomate, 1996 – Teaching Assistant in Physiology/Endocrinology, University of California San Francisco, 1988- – Instructor in Physiology/Endocrinology, University of California San Francisco, 1990. – Assistant Professor of Pathology and Biochemistry, University of Southern California, 1996- – Biochemistry and physiology tutor for 1st and 2nd year medical students, UCSF, 1988-1990 – Office hours and review lectures on cardiovascular, respiratory, and renal physiology (Physiology 100) for 1st year medical students, UCSF, 1988-1989 – Office hours and review lectures on gastrointestinal and endocrine physiology (Physiology 101) for 1st year medical students, UCSF, 1988-1989 Expert Witness Statement – Noriyuki Kasahara – Discussion section and lab instructor in cardiovascular, respiratory and renal physiology course (Physiology 100) for 1st year medical students, UCSF, 1990 – Cancer Center Grand Rounds, USC, 1996 "Targeting Viral Vectors to Cancer Cells" (lecture) – Liver Disease Research Center Seminar, USC, 1997 "Targeting Gene Delivery via Ligand-Receptor Interaction" (lecture) – Pathology Grand Rounds (for pathology residents/fellows/technologists), USC, 1997 "Gene Therapy Techniques" (lecture) – Pulmonary Division Research Seminar (for pulmonary medicine fellows), USC, 1997 "Gene Delivery to the Lung" (lecture) – Seminars in Pathology (PATH 570) course instructor, USC, 1997 & 2000 (Dept. of Pathology/course director: Dr. Cheng-Ming Chuong) "Topics in Gene Therapy" (lectures & discussion) – Human Molecular Genetics (BIOC 599) course instructor, USC, 1998 & 1999 (Dept. of Biochemistry/course directors: Dr. Jane Fountain & Dr. Sita Reddy) "Gene Therapy: Vectors" (lecture & final exam) – Recent Advances in Molecular Biology (BIOC 599) course co-director, USC, 1998 (Dept. of Biochemistry/course directors: Dr. Zoltan Tokes & Dr. Noriyuki Kasahara) – Methods in Pathology (PATH 552B) course co-coordinator, USC, 1998 & 1999 (Dept. of Pathology/course directors: Dr. Louis Dubeau & Dr. Noriyuki Kasahara) – Methods in Pathology (PATH 552B) course coordinator, USC, 2000 & 2001 (Dept. of Pathology/course director: Dr. Noriyuki Kasahara) – Supervision of laboratory research for Pathology and Biochemistry graduate students, 1996- Toshiaki Shichinohe, M.D. Ph.D. (Post-doctoral fellow) (M.S. degree, Biochemistry, graduated Spring 1999) (M.S. degree, Biochemistry, graduated Summer 1999) Expert Witness Statement – Noriyuki Kasahara (M.S. degree, Pathology, graduated Summer 1999) (M.S. degree, Biochemistry, graduated Spring 2000) – Member of Qualifying Exam Committees for the following students in 1997 – 2**1 Hector Aguilar (Ph.D. student, Biochemistry) Sunyoung Lee (Ph.D. student, Biochemistry) Vincent Lee (Ph.D. student, Biochemistry) Eleanora Goldberg (Ph.D. student, Biochemistry) Christopher Logg (Ph.D. student, Pathology) Richard McHugh (Ph.D. student, Pathology) Mariana Keshmeshian (Ph.D. student, Pathology) Samira Kaissi (Ph.D. student, Biochemistry) Timothy Hung-Po Chen (Ph.D. student, Biochemistry) Cindy Eads (Ph.D. student, Biochemistry) Martha Pao (Ph.D. student, Biochemistry) Phini Strati (Ph.D. student, Biochemistry) Harris Soifer (Ph.D. student, Biochemistry) Jiapeng Huang (Ph.D. student, Biochemistry) Xinhua Chen (Ph.D. student, Biological Sciences) Brian Roehmholdt (Ph.D. student, Cell & Neurobiology) Dennis Haas (Ph.D. student, Microbiology & Immunology) Tanja Gruber (Ph.D. student, Microbiology & Immunology) Chien-Kuo Tai (Ph.D. student, Pathology) Saswati Hazra (Ph.D. student, Pathology) Ilias Christodoulopoulos (Ph.D. student, Biochemistry) Brett Ball (Ph.D. student, Biochemistry) Jun Zuo (Ph.D. student, Microbiology & Immunology) Suzanne Peterson (Ph.D. student, Microbiology & Immunology) Expert Witness Statement – Noriyuki Kasahara Jennifer Zhong (Ph.D. student, Pathology) Erik Harboe-Schmidt (Ph.D. student, Biochemistry) Laurent Yoon (Ph.D. student, Biochemistry) Paolo Abada (Ph.D. student, Biochemistry) (a) Specific Administrative Responsibilities – Director, Research Vector Core, Institute for Genetic Medicine, University of Southern California, – Co-Director, Molecular Biology Core/Vector Subcore, USC Research Center for Liver Diseases, University of Southern California, 1999-present. – Member, Annual Departmental Retreat Planning Committee, Dept. of Biochemistry , University of Southern California School of Medicine, 1999. – Member, Graduate Admissions and Education Committee, Dept. of Pathology, University of Southern California School of Medicine, 2000-present. (2) School of Medicine committees – Member, Interdepartmental Basic Science Seminar Series Committee, University of Southern California, 1997-present. – Chair, Interdepartmental Basic Science Seminar Series Committee, University of Southern California, 1998-present. – Member, Institutional Biosafety Committee, University of Southern California School of Medicine, 1998-present. – Member, Executive Committee, Research Center for Liver Diseases, University of Southern California School of Medicine, 1999-present. – Member, Interdepartmental Graduate Program (PIBBS) Admissions Committee, University of – Member, Institutional Biosafety Committee (re-formed as university-wide committee), Expert Witness Statement – Noriyuki Kasahara University of Southern California, 2000-present. MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS: – Member, Norris Comprehensive Cancer Center, University of Southern California, 1996-present. – Member, IGM/Norris Joint Gene Therapy Program, University of Southern California, 1996- – Member, USC Research Center for Liver Diseases, University of Southern California,. 1997- – Chair, Cancer Gene Therapy session, 7th annual meeting of the Japan Society of Gene Therapy, – Japan Society for Cancer Chemotherapy, 1986-present. – American Association for the Advancement of Science, 1988-present. – American Society for Microbiology, 1994-present. – American Society of Biochemistry & Molecular Biology, 1997-present. – American Society of Gene Therapy, 1998-present. – Japan Society of Gene Therapy, 2001-present. (a) Local
– Scientific consultant, Invogene Inc., 1996–1999. – Member, Study section for Childrens Hospital Los Angeles (CHLA) Postdoctoral Research – Member, Pre-review committee for Margaret Early Research Trust grant application submissions, – Scientific consultant, Genetic Biotechnology Ventures Inc., 1999-2000. – Scientific consultant, IntraGene Sciences Inc., 2000–present. – Member, Ad-hoc study section for NIH (National Institute for Neurological Disorders and Stroke), – Manuscript reviewer, Human Gene Therapy, 1996–present. Expert Witness Statement – Noriyuki Kasahara – Manuscript reviewer, Journal of Virology, 1997–present. – Manuscript reviewer, Pharmaceutical Research, 1999–present. – Manuscript reviewer, Leukemia, 2000–present. – Member, Editorial Board, Cancer Gene Therapy, 2001–present. – Development of improved viral vectors for human gene therapy. – Targeting of gene transfer to specific tissues or cell types. – Mechanisms of carcinogenesis, and gene therapy for cancer. – Gene therapy for rheumatoid arthritis, hematopoietic disorders, and other diseases. – Use of Therapeutic Genes Encoding Secreted Proteins in Standard Vector Systems – Improving the Efficiency of Targeted Retroviral Vectors – Conditionally Replication-Competent Retroviral Vectors for Cancer Gene Therapy – Development of Novel Adenovirus-Retroelement Hybrid Vectors – Targeting Adenoviral Vectors and Adenoviral Protein-DNA Conjugates to Cancer Cells Expert Witness Statement – Noriyuki Kasahara Research Grants Obtained in the Past Five Years 1. Targeted Retroviral Vectors for Mucosal Gene Transfer. James H. Zumberge Faculty Research and Innovation Fund, 1996-1997. 2. Gene Therapy for Rheumatoid Arthritis. Wright Foundation Research Award, 1996-1997. 3. Improving Retroviral Vectors for Gene Therapy of Ovarian Cancer. 4. Targeting Adenoviral Vectors to Cancer Cells. Margaret E. Early Medical Research Trust, 1997- 5. A Novel System for Targeting Gene Delivery to Breast Cancer Cells. Cancer Foundation, 1997-1998. (as Co-Investigator; Principal Investigator: Dr. Laurence H. Kedes) 6. Targeting Adenoviral Vectors to Cancer Cells. Margaret E. Early Medical Research Trust, 1998- 7. Improving Retroviral Vectors for Gene Therapy of Breast Cancer. USC/Norris Breast Cancer Research Program, 1998. 8. Targeting Gene Delivery via the LDL Receptor. USC Liver Disease Research Center Pilot Project Program, 1998-1999. 9. USC Liver Disease Research Center New Investigator Award. Center Pilot Project Program, 1998-1999. 10. Improving Stem Cell-Targeted Gene Therapy for Thalassemia. Cooley's Anemia Foundation Research Fellowship Award, 1998. 11. Improving Retroviral Vectors for Gene Therapy of Prostate Cancer. Center Core Grant Translational Pilot Project Program, 1998-1999. 12. A Novel System for Targeting Gene Delivery to Breast Cancer Cells. Cancer Foundation, 1998-2000 (competitive renewal). (as Co-Investigator; Principal Investigator: Dr. Laurence H. Kedes) 13. Development of Novel Adenovirus-Retroelement Hybrid Vectors. 14. Development of Adenoviral Protein-DNA Conjugate Vectors. NIH grant #1 R41 CA81818-01 (NCI), 1999-2000. 15. Improving Stem Cell-Targeted Gene Therapy for Thalassemia. Cooley's Anemia Foundation Research Fellowship Award, 1999 (competitive renewal). 16. Anti-Inflammatory Gene Therapy for Rheumatoid Arthritis. 17. Anti-Angiogenic Gene Therapy for Rheumatoid Arthritis. Expert Witness Statement – Noriyuki Kasahara 18. Improving Retroviral Vectors for Gene Therapy of Breast Cancer. Breast Cancer Research Program grant #BC980554, 1999-2002. 19. A Novel Gene Delivery System Targeted to Breast Cancer Cells. Department of Defense Breast Cancer Research Program grant #BC980325, 1999-2002. (as Co-Investigator; Principal Investigator: Dr. Laurence H. Kedes) 20. Investigating the Role of Klotho as a Humoral Factor Implicated in Age Related Disease Pathogenesis. American Federation for Aging Research grant, 1999-2001. 21. Adenoviral-Mediated Anti-Angiogenic Gene Therapy for Bladder Cancer. American Cancer Society Research Project grant RPG-99-355-01-MGO, 1999-2002. (as Co-Investigator; Principal Investigator: Dr. Bernard H. Bochner) 22. Anti-Angiogenic Gene Therapy for Breast Cancer. 23. Targeting Retroviral Gene Delivery to Breast Cancer. 24. Targeted Delivery of an Anti-Breast Tumor Agent. 6EB-0059, 2000-2002. (as Co-Investigator; Principal Investigator: Dr. Francis S. Markland, Jr.) 25. Improving Retroviral Vectors for Gene Therapy of Prostate Cancer. Cancer Research Program grant #PC991159, 2000-2002. 26. Transcriptional Targeting of Retroviral Replication to Tumors. NIH grant #1 R01 CA85908 (NCI), 2000-2004. 27. Transcriptional Targeting of Retroviral Replication to Tumors. 27. Investigating the Role of Klotho in Age-Related Disease Pathogenesis. Wright Foundation Research Award, 2001-2002. 29. Gene Therapy for Dystrophic Epidermolysis Bullosa. NIH grant #1 R01 AR047981-01 (NIAMSD), 2001-2005. (as Co-Investigator; Principal Investigator: Dr. Mei Chen) 30. Cellular Transduction by Retrotransposon-Adenovirus Hybrid Vectors. NIH grant #1 R01 CA93709-01 (NCI), 2001-2006. Expert Witness Statement – Noriyuki Kasahara Sakamoto, S., Iwama, T., Ebuchi, M., Tsukada, K., Sagara, T., Kawasaki, T., Murakami, S.,
Kasahara, N., Kudo, H., and Okamoto, R.
Increased activities of thymidine kinase isozymes in human mammary tumors. British Journal of Surgery, 73: 272-273, 1986. Kasahara, N., Kawasaki, T., Kudo, H., Okamoto, R., Kawachi, Y., Murakami, S.,
Iwama, T., Yaegashi, K., and Mishima, Y. Thymidylate synthetase and thymidine kinase activities in DMH-induced colon carcinomas in rats and effects of UFT. Bulletin of Tokyo Medical and Dental University, 33: 137-144, 1986. Sakamoto, S., Kuwa, K., Tsukada, K., Sagara, T., Kasahara, N., and Okamoto, R.
Relative activities of thymidylate synthetase and thymidine kinase in 1,2-dimethylhydrazine-induced colon carcinomas in rats. Carcinogenesis, 8: 405-408, 1987. Sakamoto, S., Kudo, H., Kawasaki, T., Kuwa, K., Kasahara, N., Sassa, S., and Okamoto, R.
Effects of a Chinese herbal medicine, keishi-bukuryo-gan, on the gonadal system of rats. Journal of Ethnopharmacology, 23: 151-158, 1988. Sakamoto, S., Kudo, H., Kawasaki, T., Kasahara, N., and Okamoto, R.
Effect of ba-wei-di-huang-wan (hachimi-jio-gan) on thymidine kinase and its isozyme activities in the prostate glands in rats. American Journal of Chinese Medicine, 16: 29-36, 1988. Sakamoto, S., Hirai, H., Taga, H., Uchikoshi, T., Sunaga, T., Endo, Y., Kuwa, K., Kudo, H.,
Kawachi, Y., Kasahara, N., and Okamoto, R.
Thymidine kinase and alpha-fetoprotein as biochemical markers of hepatocarcinogenesis induced by 3'-methyl-4-dimethylaminoazobenzene treatment in rats. Carcinogenesis, 11: 145-150, 1990. Sakamoto, S., Hirai, H., Taga, H., Uchikoshi, T., Sunaga, T., Endo, Y., Kudo, H., Kato, T.,
Kasahara, N., Kuwa, K., and Okamoto, R.
Inhibition by 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil of hepatocarcinogenesis induced by 3'-methyl-4-dimethylaminoazobenzene in rats. Anticancer Research, 11: 561-566, 1991. Sakamoto, S., Kudo, H., Kuwa, K., Suzuki, S., Kato, T., Kawasaki, T., Nakayama, T., Kasahara,
N., and Okamoto, R.
Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats. American Journal of Chinese Medicine, 19: 233-41, 1991. Expert Witness Statement – Noriyuki Kasahara Kasahara, N., Kudo, H., and Iwama, T.
Effects of carcinogenesis on colonic thymidine kinase activity in familial adenomatous polyposis. Carcinogenesis, 13: 873-876, 1992. Sakamoto, S., Mizuno, M., Sawaki, K., Kudo, H., Kasahara, N., Suzuki, S., Mori, T., and
Suppression by 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil of preneoplastic mammary hyperplastic alveolar nodule formation in SHN virgin mice. Anticancer Research, 12: 1291-1294, 1992. Kudo, H., Sakamoto, S., Suzuki, S., Kuwa, K., Nakayama, T., Sugiura, Y., Kasahara, N.,
Tomiyama, J., and Adachi, Y.
Thermal effects on DNA synthesis in bone marrow cells of patients with acute myeloblastic leukemia. Anticancer Research, 12: 1543-1547, 1992. Sakamoto, S., Mori, T., Sawaki, K., Sassa, S., Suzuki, S., Sugiura, Y., Kudo, H., Kasahara, N., and
Nagasawa, H.
Effects of danazol on DNA synthesis in rat prostate. Sakamoto, S., Mori, T., Sawaki, K., Kawachi, Y., Kuwa, K., Kudo, H., Suzuki, S., Sugiura, Y.,
Kasahara, N., and Nagasawa, H.
Effects of kampo (Japanese herbal) medicine "sho-saiko-to" on DNA-synthesizing enzyme activity in 1,2-dimethylhydrazine-induced colonic carcinomas in rats. Planta Medica, 59: 152-154, 1993. Sakamoto, S., Tajima, M., Sawaki, K., Suzuki, S., Kudo, H., Sassa, S., Kuwa, K., Sugiura, Y.,
Kasahara, N., and Nagasawa, H.
Effects of luteinizing hormone-releasing hormone analogue on DNA synthesis in rat prostate and uterus. Sakamoto, S., Muroi, N., Matsuda, M., Tajima, M., Kudo, H., Kasahara, N., Suzuki, S., Sugiura,
Y., Kuwa, K., Namiki, H., and Nagasawa, H.
Suppression by kampo medicines in preneoplastic mammary hyperplastic alveolar nodules of SHN virgin mice. Planta Medica, 59: 425-427, 1993. Suzuki, S., Sakamoto, S., Kudo, H., Sassa, S., Sugiura, Y., Kuwa, K., Kasahara, N., Mori, T., and
Nagasawa, H.
Effects of danazol on endometrial DNA synthesis in rats. Expert Witness Statement – Noriyuki Kasahara Sakamoto, S., Mizuno, M., Kudo, H., Suzuki, S., Kasahara, N., Sugiura, Y., Mori, T., and
Nagasawa, H.
Suppression of mammary tumors by oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil in SHN virgin mice. Anti-Cancer Drugs, 4: 651-655, 1993. 18. Kasahara,
Deletional analysis of the human renin promoter: transcriptional activation by the SV40 enhancer enables identification of promoter regulatory elements in non-renin-expressing cells. Bulletin of Tokyo Medical and Dental University, 40: 79-91, 1993. 19. Kasahara,
N., Dozy, A., and Kan, Y.W.
Tissue-specific targeting of retroviral vectors via ligand-receptor interaction. Kasahara, N., and Kan, Y.W.
Ligand-directed targeting of retroviral vectors to human breast cancer cells. Proceedings of the National Academy of Sciences USA, 92: 9747-9751, 1995. Kasahara, N., Hamamori, Y. and Kedes, L.
A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. Journal of Molecular and Cellular Cardiology, 31: 2037-2047, 1999. Smith, E., Redman, R. A., Logg, C. R., Coetzee, G. A., Kasahara, N., and Frenkel, B.
Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle: dissociation of cyclin A/cdk2 from E2F4/p130 complexes. Journal of Biological Chemistry, 275: 19992-20001, 2000. Chen, M., O'Toole, E. A., Muellenhoff, M., Medina, E., Kasahara, N., and Woodley, D. T.
Development and characterization of a recombinant truncated type VII collagen "minigene": implication for gene therapy of dystrophic epidermolysis bullosa. Journal of Biological Chemistry, 275: 24429-24435, 2000. Song, Z., Powell, W. C., Kasahara, N., van Bokhoven, A., Miller, G. J., and Roy-Burman, P.The
effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their
interaction with stromal cells.Cancer Research, 60: 6730-6736, 2000.
Lin, A. H., Kasahara, N., Wu, W., Stripecke, R., Anderson, W. F., and Cannon, P. M.
Receptor-specific targeting mediated by the co-expression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein. Human Gene Therapy, 12: 323-332, 2001. Expert Witness Statement – Noriyuki Kasahara Kasahara, N., and Kedes, L.
3PO, a novel non-viral gene delivery system using engineered Ad5 penton proteins. Logg, C. R., Logg, A. , Tai, C. K., Cannon, P. M., and Kasahara, N.
Genomic stability and natural selection of murine leukemia viruses containing insertions at the env-3' UTR boundary Journal of Virology, 75: 6989-6998, 2001. Logg, C. R., Logg, A., Tai, C. K., Anderson, W. F., and Kasahara, N. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors in vivo Human Gene Therapy, 12: 921-932, 2001. Soifer, H., Higo, C., Kazazian, H. H., Moran, J. V., Mitani, K., and Kasahara, N.
Stable integration of transgenes delivered by a retrotransposon-adenovirus hybrid vector Human Gene Therapy, 12: 1417-1428, 2001. Chang, Z., Pan, J., Logg, C., Kasahara, N., and Roy-Burman, P.
A replication-competent feline leukemia virus subgroupA (FeLV-A) tagged with GFP reporter exhibits biological properties similar to the parental FeLV-A. 2. Journal of Virology, 75: 8837-8841, 2001.
3. 31. Kasahara, N.
Cell-specific targeting of retroviral vectors via ligand-receptor interaction. Ph.D. thesis, University of California San Francisco, 1994. Kasahara, N.
Current topics: Development of tissue-specific retroviral vectors for gene therapy. Experimental Medicine, 13: 72 (1176) –75 (1179), 1995. Kasahara, N., Dozy, A., and Kan, Y.W.
Tissue-specific targeting of retroviral vectors via ligand-receptor interaction. Advanced Drug Delivery Reviews, 17: 227-234, 1995. Yoon, L. T. K., Shichinohe, T., Laquerre, S., and Kasahara, N.
Selectively Replicating Adenoviruses for Oncolytic Therapy. Current Cancer Drug Targets, 1: 85-106, 2001. (Invited review article) Shichinohe, T., Powell, W., Roy-Burman, P., and Kasahara, N.
Expert Witness Statement – Noriyuki Kasahara Anti-angiogenesis strategies for gene therapy of cancer. Invited review article for Current Gene Therapy, manuscript in preparation. Weber, E., Anderson, W. F., and Kasahara, N.
Recent advances in retrovirus-mediated gene therapy. Invited review article for Current Opinion in Molecular Therapeutics, manuscript in preparation. Soifer, H., Anderson, W. F., and Kasahara, N.
Chimeras and Trojan horses: progress in the development of hybrid virus vectors for gene delivery. Invited review article for Human Gene Therapy, manuscript in preparation. Kasahara, N., and Kedes, L.
Non-viral gene delivery to human breast cancer cells by targeted Ad5 penton proteins. Shichinohe, T., Nishida, M., Hegerich-Gilliam, S., Naldini, L., Bochner, B. H., and Kasahara, N.
Development of lentivirus vectors for anti-angiogenic gene therapy. Cancer Gene Therapy, in press. Borok, Z., Harboe-Schmidt, J.-E., Brody, S. L., You, Y., Cannon, P., Kim, K.-J., Crandall, E. D. and
Kasahara, N.
VSV-G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells. Journal of Virology, in press. Sakamoto, S., Kawasaki, T., Kawachi, Y., Kasahara, N., Kuwa, K., Kudo, H., and Okamoto, R.
Effects of prolactin and estrogen on DNA-synthesizing enzymes in chemical carcinogen-induced rat mammary tumors. (Abstract presented at the Fifth International Congress on Prolactin, Kyoto, Japan, July 13-16, 1988. ) 2. Kasahara,
N., Dozy, A., Kan, Y.W.
Targeted gene delivery by retroviruses with peptide hormone sequences engineered into the envelope. Expert Witness Statement – Noriyuki Kasahara (Abstract presented at the UCLA Symposium on Gene Therapy, Keystone, CO, April 12-18, 1993. ) Journal of Cellular Biochemistry Supplement 17 Part E: 237, 1993. 3. Kasahara,
N., Dozy, A. M., and Kan, Y. W.
Erythroid cell-specific targeting of retroviral vectors. (Abstract selected for oral presentation at the 9th Conference on Hemoglobin Switching, Orcas Island, WA, June 10-14, 1994. ) 4. Kasahara,
N., Dozy, A., Kan, Y.W.
Tissue-specific gene delivery by retroviruses with targeting ligand sequences engineered into the envelope. (Abstract presented at the Cold Spring Harbor Symposium on Gene Therapy, Cold Spring Harbor, NY, September 21-25, 1994. ) Kasahara, N., Kan, Y.W.
Ligand-mediated retroviral targeting to human breast cancer cells. (Abstract presented at the Cold Spring Harbor Symposium on Gene Therapy, Cold Spring Harbor, NY, September 21-25, 1994. ) Kasahara, N., Cowan, M. J., Kan, Y.W.
Targeted gene delivery via human stem cell factor ligand and c-kit receptor interaction. (Abstract presented at the 36th Annual Meeting of the American Society of Hematology, Nashville, TN, December 2-5, 1994. ) Kasahara, N., and Kan, Y. W.
Ligand-directed retroviral targeting of human breast cancer cells. (Abstract presented at the Keystone Symposium on Gene Therapy and Molecular Medicine, Steamboat Springs, CO, March 26-April 1, 1995. ) Journal of Cellular Biochemistry Supplement 21A: 407, 1995. Kasahara, N., Dozy, A., Cowan, M. J., and Kan, Y. W.
Targeted retroviral gene delivery through stem cell factor-c-kit receptor interaction. (Abstract presented at the Keystone Symposium on Gene Therapy and Molecular Medicine, Steamboat Springs, CO, March 26-April 1, 1995. ) Journal of Cellular Biochemistry Supplement, 21A: 415, 1995. Expert Witness Statement – Noriyuki Kasahara Kasahara, N., Morgan, D., Kan, Y. W., and Shohet, S. B.
A beta-spectrin-green fluorescent protein fusion construct for structural analysis of the red cell membrane skeleton. (Abstract presented at the 37th Annual Meeting of the American Society of Hematology, Seattle, Washington, December 2-5, 1995. ) Wu, W., and Kasahara, N.
Investigating mechanisms of entry by use of retroviruses targeted to the LDL receptor. (Abstract selected for oral presentation at the Cold Spring Harbor Biotechnology Symposium on Vector Targeting Strategies for Therapeutic Gene Delivery, Cold Spring Harbor, New York, March 14-16, 1997. ) Medina-Kauwe, L, Taylor, E., Kasahara, N., Kedes, L.
A novel gene delivery system for cell-specific targeting. (Abstract presented at the UCLA Keystone Symposium on Molecular and Cellular Biology of Gene Therapy, Snowbird, Utah, April 13-19, 1997. ) Kaissi, S., Perkins, C., and Kasahara, N.
Targeted mutagenesis of the ecotropic murine leukemia virus receptor. (Abstract presented at the Fourth West Coast Retrovirus Meeting, Newport Beach, California, October 2-4, 1997.) Wu, W., Empig, C., Zhao, Y., Cannon, P., and Kasahara, N.
Investigating mechanisms of entry by retroviral vectors targeted to the LDL receptor. (Abstract presented at the Fourth West Coast Retrovirus Meeting, Newport Beach, California, October 2-4, 1997.) Logg, C. L., Gordon, E. M., and Kasahara, N.
Replication-competent retroviral vectors for use in gene therapy of solid tumors. (Abstract presented at the Fourth West Coast Retrovirus Meeting, Newport Beach, California, October 2-4, 1997.) Higo, C., Jih, L., Chan, R., Mitani, K., and Kasahara, N.
Development of a novel adenovirus-retrovirus hybrid gene delivery vector. (Abstract presented at the UCLA Keystone Symposium on Gene Therapy Strategies for Hematopoietic Cells, Incline Village, Nevada, January 10-15, 1998.) Expert Witness Statement – Noriyuki Kasahara Kasahara, N., and Kedes, L.
Recombinant adenovirus capsid proteins for targeted gene delivery. (Abstract presented at the UCLA Keystone Symposium on Synthetic Non-Viral Gene Delivery Systems, Keystone, Colorado, January 19-25, 1998. ) Stripecke, R., Wu, W., Kohn, D. B., and Kasahara, N.
FLT3L-directed retroviral targeting of human hematopoietic cells. (Abstract presented at the 1st Annual Meeting of the American Society of Gene Therapy, Seattle, Washington, May 28-31, 1998.) Logg, C. R., Liu, P., Gordon, E. M., Hall, F. L., Anderson, W. F., and Kasahara, N.
A novel replication-competent retrovirus vector for highly efficient gene delivery to solid tumors. (Abstract presented at the 1st Annual Meeting of the American Society of Gene Therapy, Seattle, Washington, May 28-31, 1998.) Soifer, H., Higo, C., Jih, L., Mitani, K., Swergold, G., Moran, J., Kazazian, H. and Kasahara, N.
Development of a novel retrotransposon-adenovirus hybrid vector. (Abstract presented at the Cold Spring Harbor Symposium on Gene Therapy, Cold Spring Harbor, New York, September 24-27, 1998.) Kasahara, N., Stripecke, R., Wu, W., Chang, T., Empig, C., Medina-Kauwe, L., Kohn, D., Cannon,
P., and Anderson, W. F.
Developing new strategies to enhance entry of targeted retrovirus vectors. (Abstract selected for oral presentation at the 2nd Cold Spring Harbor Biotechnology Symposium on Vector Targeting Strategies for Therapeutic Gene Delivery, Cold Spring Harbor, New York, March 19-21, 1999. ) 21. Powell, W. C., Song, Z., Lee, M., Kasahara, N., and Roy-Burman, P.
A tissue specific, bicistronic gene therapy vector to control prostate cancer. (Abstract presented at the 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, Pennsylvania, April 10-14, 1999.) Proceedings of theAmerican Association for Cancer Research Annual Meeting, 40: 235, 1999. 22. Song, Z., Powell, W. C., Zhang, L., Kasahara, N., and Roy-Burman, P.
FGF8, isoform b: A target molecule for therapy of prostate cancer. (Abstract presented at the 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, Pennsylvania, April 10-14, 1999.) Expert Witness Statement – Noriyuki Kasahara Proceedings of the American Association for Cancer Research Annual Meeting, 40: 525, 1999. Chen, M., O'Toole, E. A., Liu, Y. Y., Kasahara, N., and Woodley, D. T.
Corrective gene transfer in dystrophic epidermolysis bullosa. (Abstract presented at the 60th Annual Meeting of the American Society for Investigative Dermatology, Chicago, Illinois, May 1999.) Journal of Investigative Dermatology, 112 (4): 552, 1999. Kasahara, N., Wu, W., Stripecke, R., Kohn, D. B., Logg, C., Medina-Kauwe, L. K., Cannon, P. M.,
and Anderson, W. F.
New strategies to enhance transduction efficiency by targeted retroviral vectors. (Abstract presented at the 2nd Annual Meeting of the American Society of Gene Therapy, Washington DC, June 9-13, 1999.) Medina-Kauwe, L. K., Chen, X., Wu, L., Su, B., Leung, V., Kasahara, N., and Kedes, L.
Functional studies of Ad5 capsid proteins: implications for targeting and non-viral gene delivery. (Abstract presented at the 2nd Annual Meeting of the American Society of Gene Therapy, Washington DC, June 9-13, 1999.) Kaissi, S., Harboe-Schmidt, J.-E., Kuro-o, M., and Kasahara, N.
Gene delivery of Klotho: A humoral factor implicated in age-related disease pathogenesis. (Abstract presented at the 52nd Annual Scientific Meeting of the Gerontological Society of America, San Francisco, CA, November 19-23, 1999.) Kasahara, N., Pepper, K. A., Skelton, D. C., Xu, X. J., Mascarenhas, L., Weinberg,
Development of lentiviral vectors for immuno-gene therapy of acute leukemias. (Abstract presented at the 1999 Annual Meeting of the American Society of Hematology, New Orleans, Louisiana, December 6-10, 1999.) Shichinohe, T., Nishida, M., Jih, L., Bochner, B. H., and Kasahara, N.
Development of adenovirus and lentivirus vectors for anti-angiogenic gene therapy. (Abstract selected for oral presentation at the 8th International Conference on Gene Therapy of Cancer, San Diego, California, December 9-11, 1999.) Cancer Gene Therapy supplement 6 (6): S2-S3, 1999. Soifer, H., Higo, C., Suzuki, S., Mitani, K., Moran, J., Kazazian, H., and Kasahara, N.
Expert Witness Statement – Noriyuki Kasahara Novel hybrid vectors that mediate stable integration via retroelements encoded by helper-dependent adenoviruses. (Abstract presented at the UCLA Keystone Symposium on Molecular and Cellular Biology of Gene Therapy, Keystone, Colorado, January 6-12, 2000.) Shichinohe, T., Bochner, B. H., Nishida, M., Hegerich-Gilliam, S., and Kasahara, N.
Adenoviral- and lentiviral-mediated gene transfer of angiostatin, endostatin, and thrombospondin-1 for gene therapy of cancer. (Abstract presented at the UCLA Keystone Symposium on Molecular and Cellular Biology of Gene Therapy, Keystone, Colorado, January 6-12, 2000.) Harboe-Schmidt, J. E., Kaissi, S., Kasahara, N., Kim, K. J., Crandall, E. D. and Borok, Z.
Efficient transduction of primary cultured alveolar epithelial cells by lentiviral vectors. (Abstract selected for oral presentation at the FASEB Experimental Biology 2000 meeting, San Diego, California, April 15-18, 2000.) FASEB Journal supplement 14 (4): A650, 2000. Borok, Z., Li, X., Zhou, B., Kasahara, N., Harboe-Schmidt, J.E., Liebler, J., Ann, D.K., and
Crandall, E.D.
5'-flanking region of the rat aquaporin-5 gene directs selective expression in lung and salivary cells. (Abstract presented at the American Lung Association/American Thoracic Society 2000 International Conference, Toronto, Canada, May 5-10, 2000.) Chen, M., Tahk, S. H., Costa, F. K., Kasahara, N., and Woodley, D. T.
Recombinant expression of full-length type VII collagen alpha chains: structural and functional characterization and implications for gene therapy. (Abstract presented at the 61st Annual Meeting of the American Society for Investigative Dermatology, Chicago, Illinois, May 10-14, 2000.) Journal of Investigative Dermatology, 114 (4): 756, 2000. Logg, A., Logg, C., Matusik, R. J., Bochner, B. H., and Kasahara, N.
Targeting retroviral replication to prostate tumors. (Abstract presented at the 3rd Annual Meeting of the American Society of Gene Therapy, Denver, Colorado, May 31-June 4, 2000.) Molecular Therapy, 1 (5): S115-116, 2000. Kasahara, N., and Kedes, L.
Nonviral gene delivery to human breast cancer cells by targeted Ad5 penton proteins. Expert Witness Statement – Noriyuki Kasahara (Abstract presented at the 3rd Annual Meeting of the American Society of Gene Therapy, Denver, Colorado, May 31-June 4, 2000.) Molecular Therapy, 1 (5): S305, 2000. Stripecke, R., Cardoso, A., Vieira, A. P. Z., Kasahara, N., and Levine, A.
Immuno-gene therapy for acute myeloid leukemia: pre-clinical evaluation of third generation lentiviral vectors. (Abstract selected for oral presentation at the Cold Spring Harbor Symposium on Gene Therapy, Cold Spring Harbor, New York, September 25-29, 2000. ) Shichinohe, T., Nishida, M., Hegerich-Gilliam, S., Bochner, B. H., and Kasahara, N.
Comparison of lentivirus and adenovirus vectors for anti-angiogenic gene therapy. (Abstract selected for oral presentation at the Cold Spring Harbor Symposium on Gene Therapy, Cold Spring Harbor, New York, September 25-29, 2000. ) Soifer, H., Higo, C., Jih, L., Kazazian, H., Moran, J., Mitani, K., and Kasahara, N.
Helper-dependent adenovirus vectors encoding retrovirus or retrotransposon elements: hybrid vectors that mediate stable integration via a two-stage mechanism. (Abstract presented at the Cold Spring Harbor Symposium on Gene Therapy, Cold Spring Harbor, New York, September 25-29, 2000. ) Tai, C. K., Shichinohe, T., Nishida, M., Hegerich-Gilliam, S., Bochner, B. H., and Kasahara, N.
Comparative utility of lentivirus and adenovirus vectors for anti-angiogenic gene therapy. (Abstract selected for oral presentation at the 9th International Conference on Gene Therapy of Cancer, San Diego, California, December 7-9, 2000.) Cancer Gene Therapy supplement 7 (12): S15. Logg, C. R., Logg, A., Tai, C.-K., Park, J., Press, M. F., Bochner, B. H., Anderson, W. F., Cannon,
P. M., and Kasahara, N.
Targeting gene delivery to cancer cells using replication-competent retrovirus vectors. (Abstract selected for oral presentation at the 3rd Cold Spring Harbor Biotechnology Symposium on Vector Targeting Strategies for Therapeutic Gene Delivery, Cold Spring Harbor, New York, March 15-18, 2001. ) Wang, Y., Yarber, F. A., Mazurek, C. M., Kasahara, N., and Hamm-Alvarez, S. F.
Adenovirus-mediated overexpression of p50/dynamitin alters basal and stimulated protein secretion in primary rabbit lacrimal acinar cells. (Abstract presented at the 2001 Annual Meeting of the Association for Research in Vision and Ophthalmology, Ft. Lauderdale, Florida, April 29-May 4, 2001.) Expert Witness Statement – Noriyuki Kasahara Investigative Ophthalmology & Visual Science supplement 42 (4): S264, 2001. Sekine, Y., He, S., Schichinohe, T., Hangai, M., Kitaya, N., Yaji, N., Spee, C., Kasahara, N.,
Hinton, D. R., and Ryan, S. J.
Adenovirus-mediated angiopoietin-1 gene transfer inhibits leaking of laser-induced choroidal neovasculature. (Abstract presented at the 2001 Annual Meeting of the Association for Research in Vision and Ophthalmology, Ft. Lauderdale, Florida, April 29-May 4, 2001.) Investigative Ophthalmology & Visual Science supplement 42 (4): S346, 2001. M., Kasahara, N., Costa, F. K., Mazurek, C. M., and Woodley, D. T.
Lentiviral vectors mediate highly efficient and sustained gene transfer in dystrophic epidermolysis bullosa skin cells. (Abstract presented at the 62nd Annual Meeting of the American Society for Investigative Dermatology, Washington DC, May 9-12, 2001.) Vieira, A. P. Z., Kasahara, N., Naldini, L., Cardoso, A., Levine, A., and Stripecke, R.
Evaluation of third generation lentiviral vectors to transduce and express CD80 and GM-CSF in human acute myeloid leukemia cell vaccines. (Abstract selected for oral presentation at the 4th Annual Meeting of the American Society of Gene Therapy, Seattle, Washington, May 29-June 3, 2001.) Medina-Kauwe, L., Maguire, M., Daoud, J., Felix-Trunelle, E., Kasahara, N., and Kedes, L.
Non-viral gene delivery by targeted adenovirus capsid proteins . (Abstract selected for oral presentation at the 4th Annual Meeting of the American Society of Gene Therapy, Seattle, Washington, May 29-June 3, 2001.) Shichinohe, T., Tai, C. K., Nishida, M., Hegerich-Gilliam, S., Naldini, L., Bochner, B. H., and
Kasahara, N.
Lentivirus vector-mediated gene delivery of endostatin results in suppression of tumor growth in vivo. (Abstract selected for oral presentation at the 4th Annual Meeting of the American Society of Gene Therapy, Seattle, Washington, May 29-June 3, 2001.) Kaissi, S., Harboe-Schmidt, J.-E., Kuro-o, M., and Kasahara, N.
Investigating the role of Klotho as a humoral factor implicated in age-related disease pathogenesis. (Abstract presented at the 14th Annual Grantee Conference of the American Federation for Aging Research, Madison, Wisconsin, June 1-4, 2001.) Expert Witness Statement – Noriyuki Kasahara Shichinohe, T., Logg, C. R., Soifer, H., Tai, C. K., Logg, A., Cannon, P. M., Anderson, W. F., and
Kasahara, N.
Development of novel vectors for anti-angiogenic gene therapy of cancer. (Abstract selected for oral presentation at the 7th Annual Meeting of the Japan Society of Gene Therapy, Tokyo, Japan, July 5-7, 2001.) Stripecke, R., Favaro, P. M. B., Koya, R. C., Kasahara, N., Weber, J. S., Levine, A. M., and
Ostertag, W.
Development of lentiviral vectors to enhance the immunogenicity of autologous leukemia and dendritic cell vaccines. (Abstract presented at the Annual Meeting of the German Society of Gene Therapy, Bavaria, Germany, July 5-7, 2001. ) He, J., Oh, J. W., Kasahara, N., and Lai, M. M. C.
Characterization of Hepatitis C virus polymerase expressed in mammalian cells: phosphorylation is essential for its polymerase activity. (Abstract selected for oral presentation at the 20th Annual Meeting of the American Society for Virology, Madison, Wisconsin, July 20-25, 2001.) Logg, C. R., Logg, A., Matusik, R. J., Bochner, B. H., and Kasahara, N.
Prostate-specific transcriptional targeting of replication-competent retrovirus vectors. (Abstract to be presented at the Harold W. Siebens Conference on Replicating Vectors for Gene Therapy, Mayo Clinic, Rochester, Minnesota, October 5-7, 2001.) Kasahara, N., Dozy, A., and Kan, Y.W. Targeting retroviral vectors to specific cells – reply. Kasahara, N., and Iwama, T.
Thymidine kinase activities in familial adenomatous polyposis, adenomatous polyps, and carcinoma of the colon. In: Familial Adenomatous Polyposis, L. Herrera, Ed., Alan R. Liss Inc., New York, 2. Kasahara,
N., Dozy, A. M., and Kan, Y. W.
Expert Witness Statement – Noriyuki Kasahara Erythroid cell-specific targeting of retroviral vectors. In: Biology of Hematopoiesis and Stem Cell Gene Transfer, G. Stamatoyannopoulos, Ed. Intercept Wang, W. P., Kasahara, N., and Chuong, C. M.
Update to: Retroviral gene transfer in chondrogenic limb bud micromass cultures. In: Expression Genetics: Accelerated and High-throughput Methods, Michael McClelland and Arthur B. Pardee, Eds. Eaton Publishing, 1999. Benedict, C., Cannon, P. M., Zhao, Y., Kasahara, N., and Anderson, W. F.
Development of retroviral vectors that target hematopoietic stem cells. In: Hematopoietic Stem Cell Therapy, Anthony D. Ho, Ed., Marcel-Dekker Inc., pp. 575-593, 1999. Kasahara, N., and Kedes, L.
Lentivirus-mediated gene transfer to cardiomyocytes. In: Cardiac Gene Transfer: Principles, Protocols, and Applications, manuscript in preparation. Nishijo, K., Sato, Y., and Kasahara, N.
Hari-no-kagaku. (A Japanese Translation of "Scientific Aspects of Acupuncture" by F. Mann.) Ishiyaku Publishing Inc., Tokyo, Japan, 1982. Setijono, N., and Kasahara, N.
Identification of malarial parasites on thin blood smears. In: Laboratory Medicine Residents' Manual (S. Cohen, Ed.), Department of Laboratory Medicine, University of California at San Francisco, 1992 & 1994. Kasahara, N., and Kan, Y. W.
Methods and Compositions for Targeting Specific Tissues. (University of California Office of Technology Transfer Case No. 92-148-2) L., Kasahara, N., and Kedes, L.
Expert Witness Statement – Noriyuki Kasahara A Novel Gene Delivery System for Cell-Specific Targeting. Provisional U.S. Patent Application No. 60/078,040 Conversion to full U.S. Patent Application No. 09/270,148 (USC Office of Technology Licensing File No. 2846) Kasahara, N., Logg, C., and Anderson, W. F.
Provisional U.S. Patent Application No. 60/102,938 Conversion to full U.S. Patent Application No. 09/409,650 (USC Office of Technology Licensing File No. 2862) Kasahara, N., Soifer, H., Higo, C., and Mitani, K.
Novel Gene Delivery Vectors Based on Retrovirus-Adenovirus Hybrids. Provisional U.S. Patent Application No. 60/116,150 Conversion to full U.S. Patent Application No. 09/484,901 (USC Office of Technology Licensing File No. 2831) J., Kasahara, N., and Lai, M.
Provisional U.S. Patent Application No. 60/157,093 (USC Office of Technology Licensing File No. 2945) Z., Kasahara, N., and Crandall, E.
Lentiviral Vectors for Gene Transfer to Alveolar Epithelial Cells. Provisional U.S. Patent Application filed (serial number pending) (USC Office of Technology Licensing File No. 2993) B. INTERNET
PRESENTATIONS
Invited presentation for “Gene Talk” at ed by DNA Sciences, Inc. Original airing date: Wed, August 16, 2000 at 8 pm EST; Transcript archive location: Expert Witness Statement – Noriyuki Kasahara Ligand-receptor mediated targeting of retroviral vectors. (Cambridge Healthtech Institute 3rd Annual Meeting on Gene Therapy: New Technologies and Applications, Arlington, VA, May 1-3, 1995.) Kasahara, N., and Kan, Y. W.
Tissue-specific retroviral vectors for gene therapy. (First International Symposium on Human Gene Therapy, Inuyama/Nagoya, Japan, September 10-13, 1995.) Kasahara, N.
Targeting retroviral vectors via ligand-receptor interaction. (Chicago Institute of Neurosurgery and Neuroresearch Symposium 1995, Chicago, Illinois, October 19-20, 1995.) Kasahara, N.
Targeting gene delivery to specific cell types. (Los Angeles City-Wide Gene Therapy Meeting, Los Angeles, California, October 24, 1996.) Kasahara, N.
Targeting gene delivery by viral vectors. (Pfizer Travelling Fellowship Lecture, Institut de Recherches Cliniques de Montreal (Clinical Research Institute of Montreal), Montreal, Canada, January 6, 1997.) Kasahara, N.
Development of gene delivery vehicles targeted to specific cell types. (2nd Annual UCLA Gene Therapy Symposium, Los Angeles, California, October 2-4, 1997.) Kasahara, N.
Improving viral vectors for gene therapy. (Cedars-Sinai Hospital Genetics Division research seminar, September 11, 1997.) Kasahara, N.
Basic Science for Clinical Nephrologists: The New Vascular Biology –Gene Therapy Vectors. (Clinical Nephrology Symposium, 31st Annual Meeting of the American Society of Nephrology, Philadelphia, Pennsylvania, October 25-28, 1998.) Expert Witness Statement – Noriyuki Kasahara Kasahara, N.
Gene therapy: vector systems and clinical applications. (Department of Dermatology Residency Program educational seminar, Brown University, Providence, Rhode Island, April 16, 1999.) Kasahara, N.
Intracellular fate of targeted retroviral vectors: overcoming barriers to transduction. (USC Norris Comprehensive Cancer Center Mini-Symposia Series "Molecular Virology of Cancers", May 7, 1999.) Kasahara, N.
Gene Therapy 2000: New Strategies for Vector Development. (Division of Cardiology Basic Science Conference, Cedars Sinai Medical Center, Los Angeles, California, April 28, 2000.) Kasahara, N.
Vectors 2000: Developing New Tools for Gene Delivery In Vivo. (Gene Therapy Seminar Series, Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, May 1, 2000.) Kasahara, N.
Virus Vectors and Trojan Horses: Developing New Tools for Gene Therapy. (Molecular Medicine Program Seminar Series, Mayo Clinic, Rochester, Minnesota, July 27, 2000.) Kasahara, N.
Anti-Angiogenic Gene Therapy for Breast Cancer. (Susan G. Komen Breast Cancer Foundation 4th Annual Mission Conference, Washington D.C., Sept 17-19, 2000.) Kasahara, N.
Retroviral vectors for cardiovascular gene therapies. (Cardiovascular Gene Therapy 2000 Symposium, American Heart Association and Los Angeles Vascular Biology and Lipid Club, Cedars Sinai Medical Center, Los Angeles, California, September 21, 2000.) Kasahara, N.
Expert Witness Statement – Noriyuki Kasahara (Department of Urology research seminar, Memorial Sloan Kettering Cancer Center, New York, NY, September 30, 2000.) Kasahara, N.
Medicine in the 21st century: toward clinical application of gene therapy. (Department of Surgery post-graduate educational seminar, Tokyo Medical & Dental University, Tokyo, Japan, October 16, 2000.) Kasahara, N.
Cancer gene therapy: developing new approaches and new vectors. (Institute of Age-Related Disease Regulation research seminar, Tohoku University School of Medicine, Sendai, Japan, October 18, 2000.) 19. Kasahara, N.
Cancer gene therapy 2000: current vector technology and therapeutic strategies. (Cancer Center/ Institute of Genetic Medicine special seminar, Hokkaido University School of Medicine, Sapporo, Japan, October 20, 2000.) Kasahara, N.
(Gene Transfer Technologies Symposium, 53rd Annual Scientific Meeting of the Gerontological Society of America, Washington D.C., November 17-21, 2000.) Gerontologist 40 (S1): 303, 2000. Kasahara, N.
Therapeutic expression of secreted proteins in vivo by viral gene transfer. (Avigen Corporation research seminar, Alameda, California, May 4, 2001.) Kasahara, N.
New strategies for therapeutic expression of secreted proteins in vivo. (Tanabe Pharmaceuticals Inc., Discovery Research Laboratories seminar, Toda City, Japan, July 5, 2001.) Kasahara, N.
RCRs and Trojan Horses: New strategies for viral vector development. (Gene Therapy Seminar Series, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, to be held September 18, 2001. (postponed)) Expert Witness Statement – Noriyuki Kasahara Kasahara, N.
Targeting strategies for replication-competent retrovirus vectors. (Harold W. Siebens Conference on Replicating Vectors for Gene Therapy, Mayo Clinic, Rochester, Minnesota, to be held October 5-7, 2001.) Kasahara, N.
Vectors 2001: New strategies to improve gene delivery. (Cellular Gene Delivery Symposium, 2001 American Association of Pharmaceutical Scientists Annual Meeting, Denver, CO, to be held October 21-25, 2001.) Expert Witness Statement – Noriyuki Kasahara

Source: http://techlaw.lls.edu/events/atc2001/NKasahara_statement.pdf